A Twin Study of Metabolic Syndrome and Autonomic Tone by GEHI, ANIL K. et al.
A Twin Study of Metabolic Syndrome and Autonomic Tone
Anil Gehi, MD1, Rachel Lampert, MD3, Emir Veledar, PhD2, Forrester Lee, MD3, Jack
Goldberg, PhD4, Linda Jones, BS2, Nancy Murrah, RN2, Ali Ashraf, MD2, and Viola
Vaccarino, MD, PhD2,5
1Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill
School of Medicine, Chapel Hill, NC
2Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta,
GA
3Department of Medicine, Yale University School of Medicine, New Haven, CT
4Vietnam Era Twin Registry, Seattle, WA
5Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
Abstract
Introduction—One possible mechanism of higher cardiovascular mortality associated with the
metabolic syndrome (MetS) may be through abnormal modulation in autonomic tone.
Methods and Results—We examined the association between the MetS and autonomic tone as
measured by heart rate variability (HRV) among 288 twins from the Twins Heart Study. Of the
288 participants, 151 (52%) had the MetS. The MetS was associated with decreased HRV across
all frequency ranges, and each additional MetS risk factor was associated with lower HRV. After
adjustment for several potential confounders, very-low frequency (p<0.001), low frequency
(p<0.001), and total power (p=.02) spectra of HRV remained significantly lower in twins with a
progressively higher number of MetS components (18-50% decrease comparing twins with 5 risk
factors to those with no risk factors). Among 87 twin pairs who were discordant for the number of
MetS components, a one-unit increment in MetS components was associated with an 8% smaller
very-low frequency (p=0.03) and a 15% smaller low frequency spectrum (p=0.002) comparing
each twin with his brother.
Conclusion—MetS was associated with lower HRV in a well-characterized sample of middle-
aged male twins. This association persisted even after controlling for genetic and shared
environmental factors accounted for by comparison within twin pairs. Abnormalities of autonomic
tone, as evidenced by lower HRV, may be partly responsible for the higher rate of atrial
fibrillation, coronary heart disease, cardiac death, and overall mortality seen in patients with the
MetS.
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The metabolic syndrome (MetS) is associated with the development of diabetes mellitus and
increases the likelihood of cardiovascular disease (CVD) events, including atrial fibrillation,
acute coronary syndrome, cardiac death, and overall mortality. 1-6 The risk of future CVD
events is more strongly correlated with the MetS than its individual components,2, 4
although this issue is still debated. One possible mechanism underlying the link between
MetS and CVD events is through abnormal modulation in autonomic tone, which has been
associated both with MetS and CVD risk. 7-9 Specifically, increased sympathetic activity10
and decreased parasympathetic activity11 have been associated with a higher risk of sudden
death. Both the sympathetic and parasympathetic nervous system have been implicated in
mediating atrial fibrillation.12 Experimental evidence also suggests an interaction of the
autonomic nervous system with the development of vascular atheroma and occlusion.13
Heart rate variability (HRV) is a complex measure of heart rate modulation that incorporates
both sympathetic and parasympathetic effects as well as their interaction.14, 15 When
determined from 24-hour electrocardiographic recordings, depressed HRV predicts adverse
cardiovascular events.16-18 In particular, reduced HRV is associated with an increased risk
of atrial fibrillation, myocardial infarction, congestive heart failure, coronary heart disease
death, and total mortality.16-19
While several pilot studies suggest an association between the MetS and HRV, these studies
are limited by modest sample size and short-term HRV recordings.7, 9, 20 Short-term HRV
recordings (i.e., 2-5 minutes rather than 24-hour) do not quantify the very-low and ultra-low
frequency components of HRV, which are the most powerful predictors of adverse CVD
events.14, 16 In addition, prior studies have not adjusted for important confounders such as
depression and physical activity, nor have these studies standardized the schedule and
activity of participants during ambulatory ECG recording21, 22
Studies using discordant twin pairs provide unique insight because similarities in genetic
background and early environment between twin siblings reduce variation resulting from
unmeasured potential confounders. In addition, a study utilizing twins may provide insight
into the genetic or other familial component of any association. The purpose of this study,
therefore, was to further examine the association between the MetS and autonomic tone, as
measured by HRV, using a well-controlled study of twins. In addition, a study of MetS and
autonomic function utilizing twins provides insight into the genetic and other familial
component of any association.
Methods
Participants
The Twins Heart Study (THS) is an investigation of psychological, behavioral and
biological risk factors for subclinical cardiovascular disease using twins. Participants were
selected from the Vietnam Era Twin (VET) Registry, a cohort of 7369 middle-aged male-
male twin pairs both of whom served in the United States military during the Vietnam War.
23, 24 Characteristics of the VET Registry have been previously reported.25 The THS
included 360 twins from the VET Registry all born between 1946 and 1956 (>90% of the
twins in the VET registry fall into this range). The methods of construction of this sample
were also described before 26-28. Briefly, the twins were free of a selfreported previous
diagnosis of cardiovascular disease based on survey data collected in 199029, including a
previous diagnosis of myocardial infarction, coronary heart disease, angina, congestive heart
failure or stroke, or previous coronary angioplasty or coronary bypass surgery. From this
group, random samples of twins in two strata were selected: one stratum included twins
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discordant for a lifetime history of major depression; and in a second stratum, neither twin
had a history of depression. All twins were examined, in pairs, at the Emory University
General Clinical Research Center between March 2002 and March 2006. The GCRC
admission lasted approximately 27 hours and the entire data collection for the study
occurred during this time. The two twins maintained an identical schedule while in the
GCRC under the supervision of study personnel. Activity was limited to ambulation within
the Emory facilities. All assessment, including ambulatory ECG monitoring, began and
ended at the same time. This protocol was approved by the Institutional Review Board at
Emory University, and all participants provided written informed consent.
Metabolic syndrome
We used the 2005 American Heart Association (AHA), National Heart Lung and Blood
Institute (NHLBI) definition of the MetS,30 which is based on any 3 of the following 5
criteria: waist circumference of ≥40 inches, triglycerides ≥150 mg/dL or drug treatment for
elevated triglycerides, HDL-C <40 mg/dL or drug treatment for reduced HDL-C, systolic
blood pressure (BP) ≥130 mmHg or diastolic BP ≥85 mmHg or drug treatment for
hypertension, and fasting glucose ≥100 mg/dL or drug treatment for elevated glucose.30
Heart rate variability
For the measurement of HRV, participants wore an ambulatory ECG (Holter) monitor (GE
Marquette SEER digital system) for 24 hours. Twin pairs were studied at the same time and
their recording times, schedule, and activity level during Holter monitoring were matched.
The methodology of HRV acquisition and analysis has been previously described.16, 31-33
All recordings were manually processed and edited to ensure accurate identification of QRS
complexes. For frequency domain analysis, the heart rate spectrum was computed using a
fast Fourier transformation with a Parzen window. As described previously,16 the various
bands of power spectrum were defined as follows: ultra-low frequency (ULF) < 0.0033 Hz,
very-low frequency (VLF) 0.0033 to <0.04 Hz, low frequency (LF) 0.04 to <0.15 Hz, high
frequency (HF) 0.15 to <0.40 Hz, and total power (TP) <0.40 Hz. Recordings with >20%
interpolation or <18 recorded hours of Holter data were excluded from the analysis.
Other measurements
A thorough medical history and a physical exam were obtained from all participants.
Abdominal and hip circumference was measured. Systolic and diastolic blood pressure was
measured using a standard sphygmomanometer on the right arm with the participant in the
seated position after 10 minutes of rest. Blood pressure was taken as an average of two
measurements 5 minutes apart. Venous blood samples were drawn for the measurements of
glucose and lipid profile after an overnight fast. Total triglycerides were determined by
enzymatic methods (Beckman Coulter Diagnostics, Fullerton, CA). Direct high-density
lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol were measured with
homogeneous assays (Equal Diagnostics, Exton, PA). Glucose levels were measured on the
Beckman CX7 chemistry autoanalyzer. Cigarette smoking was classified into current versus
not current smoker. Physical activity was determined by means of a modified version of the
Baecke Questionnaire of Habitual Physical Activity.34 For this analysis, we used the global
physical activity score, higher scores indicating more physically active. To measure
depressive symptoms, we administered the Beck Depression Inventory-II (BDI-II), a
standardized scale of depressive symptoms with higher scores indicating more severe
depression.35 For this analysis, we used a cut point of 14 to indicate the presence of at least
mild depression.35
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Baseline characteristics were compared between study participants with and without the
MetS. P values were corrected for the correlation between co-twins using generalized
estimating equations (GEE) for categorical variables and mixed effects models for
continuous variables. All HRV measurements were log-transformed to normalize their
distribution for analysis.
Two approaches were used to examine the association between MetS (and its individual
components) and HRV: a) considering twins as separate individuals, in which all twins were
eligible for inclusion regardless of whether their brother was available for analysis; and b)
within twin pairs approach (co-twin control analysis). The within-pair effects are inherently
controlled for demographic, shared familial (including genetics) and environmental
influences; in addition, daily activities and other environmental factors during the
ambulatory ECG recording are controlled since co-twins were examined at the same time
and under the same conditions. If an association is present both when analyzing twins as
individuals and within twin pairs, this suggests that there are not familial confounding
factors.
In the analysis of all twins as individuals, we used mixed effects regression models and
accounted for the twin pairs using a random effect term for each pair. Analyses were
repeated after adjusting for age, current smoking, depression, physical activity, medications
(beta-blocker, renin-angiotensin blocker, statin, aspirin, anti-depressant), and creatinine
clearance. To see if there was a gradient pattern to the association between MetS and HRV,
we compared the mean HRV in each frequency band for each additional component of the
MetS (from 0 components to all 5 components). To ease interpretation, and in order to
display the actual magnitude of the difference, we expressed the results as percent difference
of the nontransformed values by using the following formula: [1-(expβ)] × 100 (%).
Spearman correlation coefficients were also calculated between the individual components
of the MetS and the spectral components of HRV as continuous variables. Finally, we
compared mean HRV between individuals with and without the MetS, again adjusting for
potential confounding factors.
We then performed within-pair analyses, which examined differences in HRV between co-
twins in each pair who were discordant for the MetS component of interest. Initially we
constructed twin pair subgroups who were discordant for the MetS and for each individual
MetS component and compared HRV values between the discordant twins. Next, to examine
the cumulative impact of increasing MetS risk factors on HRV, we defined discordance as a
different number of MetS components within a twin pair. We fitted mixed effects models
adapted for twin research36 in which the within-pair parameter expressed the difference
between twins who were discordant for number of MetS components, and was analyzed as
an ordinal variable describing the departure of each twin from the pair average. These
analyses were repeated after stratification according to zygosity. A twin study design is a
useful tool in uncovering genetic influences not only on specific traits, but also on specific
associations. If the association is due to genetic factors, then it should be found within
dizygotic (DZ) twin pairs, who share on average only 50% of their genes, but not within
monozygotic (MZ) twin pairs, who share 100% of their genes. All of the analyses were
performed using Statistical Analysis Software (version 9.13, SAS Institute, Inc, Cary, NC).
Results
Analyses of all twins as individuals
From the 360 twins in this study, 288 (80%) had Holter recordings adequate for HRV
analyses (18 hours or more of recording with at least 80% noninterpolated intervals). Of
Gehi et al. Page 4













these 288 participants, 151 (52%) had the MetS. This sample included 115 twin pairs and 58
unpaired twins (resulting from exclusion of the co-twin). Twins with the MetS had higher
levels of depressive symptoms, were less physically active, and were more likely to be
taking beta-blocker, aspirin, renin-angiotensin blocker, statin, and antidepressant
medications (Table 1).
When the individual components of the MetS were considered as dichotomous variables (as
defined by the updated AHA/NHLBI criteria) in the overall sample, most of them showed
associations with at least one HRV variable. In adjusted analyses, associations persisted for
hypertriglyceridemia (p<0.05 for ULF, VLF, LF, TP, ranging from 16% to 21% lower
HRV), hypertension (p<0.05 for VLF, LF, 16% and 20% lower, respectively),
hyperglycemia (p<0.05 for LF, 17% lower), and waist circumference (p<0.05 for LF, 18%
lower). In contrast, after adjustment for possible known confounders such as physical
activity and smoking, HDL did not show significant associations with any of the HRV
frequency bands in multivariable analysis.37-40
The MetS was associated with decreased HRV across all frequency ranges when considered
as a dichotomous variable (Table 2). After adjustment for possible confounders, the VLF,
LF, and TP spectra of HRV remained significantly lower in participants with MetS. In
addition, HRV decreased progressively with higher number of MetS components (Figure 1),
and participants with all 5 components had HRV values between 18% and 50% lower than
those with no risk factors. Exclusion of participants with diabetes or coronary heart disease
resulted in no substantial change in these results.
Analyses within twin pairs
Of all twin pairs, 41 were discordant for metabolic syndrome. In general, differences in
subject characteristics showed trends similar to the analyses of twins as individuals but were
less pronounced within these matched pairs. When analyses were restricted to twin pairs
who were discordant for each MetS component, analyses of the individual components of
the MetS revealed a similar pattern to analyses of twins as individuals, although differences
were somewhat less marked. The limited number of twin pairs who were discordant for each
of the MetS components (n=24 to 42, depending on the MetS component), however,
minimized the power of this analysis. Only hypertension and waist circumference were
significantly associated (p<0.05) with HRV (VLF and LF, 24% to 40% lower for
hypertension, respectively, and from 20% to 25% lower HRV for waist circumference) in
twin pairs who were discordant for these components. When the analysis was repeated
among the 41 twin pairs who were discordant for the MetS, VLF and LF were significantly
associated with the MetS in unadjusted analysis and showed a borderline association in
adjusted analysis (Table 3).
When we considered the number of MetS components, there were 87 pairs who were
discordant for number of MetS components. Within-pair analyses for differences in HRV
between co-twins who differed for number of components confirmed a significantly lower
VLF and LF spectra of HRV for each incremental component of the MetS. After adjustment
for other covariables as above, a one-unit increment in MetS components was associated
with an 8% lower VLF (p=0.03) and a 15% lower LF spectrum (p=0.002) comparing each
twin with his brother (Table 3). Results were no different within MZ and DZ twin pairs
examined separately. Among MZ twins, who share 100% of their genetic material, for each
additional MetS component there was a 10% lower VLF (p=0.03) and a 15% lower LF
(p=0.01) HRV comparing each twin with his brother.
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We repeated analyses without adjusting for medications, which may have been prescribed
for treatment of MetS risk factors (beta-blockers, renin-angiotensin blockers and statins).
The results were very similar and are not shown.
Discussion
We found a strong and consistent association between the MetS and lower HRV in a well-
characterized sample of middle-aged male twins. There was a gradient to the association
such that participants with an increasing number of components of the MetS had
progressively lower HRV. In addition, within-pair analyses of co-twins, which accounted for
unmeasured sociodemographic, lifestyle and familial factors shared by twins being raised in
the same family, as well as environmental influences during ECG monitoring, demonstrated
a robust association of the MetS with HRV (specifically VLF and LF). Because we
demonstrated that an association between MetS and lower HRV was present in both
analyses of twins as individuals as well as within twin pairs, we also can eliminate familial
confounding factors. Of all the HRV spectra, VLF and LF showed persistent associations in
within-pair analyses, and each incremental MetS component was associated with
progressively lower VLF and LF HRV comparing co-twins.
Several prior studies have examined the association between the MetS and HRV.7, 9, 20,
41-43 The presence of the MetS in 2359 patients from the Atherosclerosis Risk in
Communities (ARIC) study was associated with reduced LF and HF components of HRV.20
In a study of 2197 participants in the Whitehall II study, each individual component of the
MetS and the MetS as a whole were associated with reduced LF and HF power components
of HRV.9 In the Cardiovascular Health Study, the presence of >2 components of the MetS
was associated with decreased ULF and TP components of HRV.43 Most of these prior
studies, however, have been limited by their measurement of short-term (LF and HF) HRV.
Importantly, short-term HRV does not measure fluctuation in beat-to-beat intervals with
cycles longer than 5 minutes. It is the VLF and ULF spectra that have the greatest prognostic
utility for CVD.14, 16 Although VLF can be calculated in short-term recordings (≤ 5 min),
it is a dubious measure and should be avoided.31 Other prior studies did not adjust for
important potential confounders, such as depression and physical activity, nor was HRV
recorded in a controlled setting.43 Our study also has the advantage of twins analyses,
which may eliminate other unmeasured confounders.
There are several important implications of our findings. These results support the integral
role of the autonomic nervous system in patients with the MetS. Whether the inciting factor
leading to the MetS is obesity44 or a primary abnormality of autonomic tone leading to a
disturbance in the hypothalamus-pituitary-adrenal axis45 is unclear. Due to the cross-
sectional design of our study, this cannot be determined from our results. As demonstrated
in the postmyocardial infarction setting and in patients without overt coronary heart disease,
abnormal HRV predicts mortality, cardiac death, and arrhythmic death.16, 18, 46 In
particular, the ULF and VLF components of HRV are more important predictors than the LF
and HF components. The VLF component, which showed a robust association with the
MetS in our study, is dependent on the presence of parasympathetic activity47 and is
associated with arrhythmic death.16
There are several strengths of our study. We assessed and adjusted for important
confounding factors associated with HRV. In addition, because participants in our study
were twins, within-pair analyses of co-twins accounted for familial and genetic factors
shared by twins. Because co-twins were examined at the same time, environmental
influences during ECG monitoring were also controlled. There are, however, several
limitations of our study to consider. Despite our controlled design, it is possible that the
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association between the MetS and HRV may be influenced by other unmeasured
confounding variables. In particular, obstructive sleep apnea has been associated with both
the MetS and HRV but was unmeasured in our population.48, 49 Also, the participants
included in our study were all male middle-aged military veterans, so the results may not
generalize to other populations.
In conclusion, in predominantly healthy middle-aged men, the MetS is associated with
decreased HRV. These findings suggest that abnormalities of the autonomic tone as
evidenced by HRV may be partly responsible for the adverse cardiovascular events such as
atrial fibrillation, sudden death, or acute coronary syndrome seen in patients with the MetS.
Acknowledgments
We gratefully acknowledge the continued cooperation and participation of the members of the Vietnam Era Twin
Registry. Without their contribution this research would not have been possible.
This work was supported by NIH (R01 HL68630, R01 AG026255, and K24HL077506); the American Heart
Association (0245115N), and Emory University General Clinical Research Center (MO1-RR00039). The United
States Department of Veterans Affairs has provided financial support for the development and maintenance of the
Vietnam Era Twin (VET) Registry. Numerous organizations have provided invaluable assistance, including: VA
Cooperative Study Program; Department of Defense; National Personnel Records Center, National Archives and
Records Administration; the Internal Revenue Service; NIH; National Opinion Research Center; National Research
Council, National Academy of Sciences; the Institute for Survey Research, Temple University.
References
[1]. Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ,
Cook TD, Edwards D, Pfeffer MA. Metabolic syndrome, C-reactive protein, and prognosis in
patients with established coronary artery disease. Am Heart J. 2006; 152:298–304. [PubMed:
16875914]
[2]. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic
syndrome and risk of incident cardiovascular events and death: a systematic review and meta-
analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49:403–414. [PubMed: 17258085]
[3]. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic
syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men
and women. Arch Intern Med. 2004; 164:1066–1076. [PubMed: 15159263]
[4]. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the
metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all
causes in United States adults. Circulation. 2004; 110:1245–1250. [PubMed: 15326067]
[5]. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor
of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112:3066–3072.
[PubMed: 16275870]
[6]. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic
syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study.
Circulation. 2008; 117:1255–1260. [PubMed: 18285562]
[7]. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M,
Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot
MG. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested
case-control study. Circulation. 2002; 106:2659–2665. [PubMed: 12438290]
[8]. Grassi G, Seravalle G. Autonomic imbalance and metabolic syndrome: unravelling interactions,
mechanisms and outcomes. J Hypertens. 2006; 24:47–49. [PubMed: 16331100]
[9]. Hemingway H, Shipley M, Brunner E, Britton A, Malik M, Marmot M. Does autonomic function
link social position to coronary risk? The Whitehall II study. Circulation. 2005; 111:3071–3077.
[PubMed: 15939818]
Gehi et al. Page 7













[10]. Miyazaki T, Zipes DP. Pericardial prostaglandin biosynthesis prevents the increased incidence of
reperfusion-induced ventricular fibrillation produced by efferent sympathetic stimulation in dogs.
Circulation. 1990; 82:1008–1019. [PubMed: 2118429]
[11]. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr. Foreman RD, Schwartz PJ. Vagal
stimulation and prevention of sudden death in conscious dogs with a healed myocardial
infarction. Circ Res. 1991; 68:1471–1481. [PubMed: 2019002]
[12]. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007; 4:S61–
64. [PubMed: 17336887]
[13]. Hamaad A, Lip GY, MacFadyen RJ. Heart rate variability estimates of autonomic tone:
relationship to mapping pathological and procedural stress responses in coronary disease. Annals
of medicine. 2004; 36:448–461. [PubMed: 15513296]
[14]. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann
Noninvasive Electrocardiol. 2005; 10:88–101. [PubMed: 15649244]
[15]. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular
disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008; 51:1725–
1733. [PubMed: 18452777]
[16]. Bigger JT Jr. Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency
domain measures of heart period variability and mortality after myocardial infarction.
Circulation. 1992; 85:164–171. [PubMed: 1728446]
[17]. Kleiger RE, Miller JP, Bigger JT Jr. Moss AJ. Decreased heart rate variability and its association
with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59:256–262.
[PubMed: 3812275]
[18]. Tsuji H, Larson MG, Venditti FJ Jr. Manders ES, Evans JC, Feldman CL, Levy D. Impact of
reduced heart rate variability on risk for cardiac events. The Framingham Heart Study.
Circulation. 1996; 94:2850–2855. [PubMed: 8941112]
[19]. Vikman S, Makikallio TH, Yli-Mayry S, Nurmi M, Airaksinen KE, Huikuri HV. Heart rate
variability and recurrence of atrial fibrillation after electrical cardioversion. Annals of medicine.
2003; 35:36–42. [PubMed: 12693611]
[20]. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, Cai J, Sharrett AR. Multiple
metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in
Communities Study. Diabetes Care. 1998; 21:2116–2122. [PubMed: 9839103]
[21]. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM,
O'Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial
infarction. Circulation. 2001; 104:2024–2028. [PubMed: 11673340]
[22]. Pannier B, Thomas F, Eschwege E, Bean K, Benetos A, Leocmach Y, Danchin N, Guize L.
Cardiovascular risk markers associated with the metabolic syndrome in a large French
population: the “SYMFONIE” study. Diabetes Metab. 2006; 32:467–474. [PubMed: 17110902]
[23]. Eisen S, True W, Goldberg J, Henderson W, Robinette CD. The Vietnam Era Twin (VET)
Registry: method of construction. Acta Genet Med Gemellol (Roma). 1987; 36:61–66. [PubMed:
3673478]
[24]. Goldberg J, Curran B, Vitek ME, Henderson WG, Boyko EJ. The Vietnam Era Twin Registry.
Twin Res. 2002; 5:476–481. [PubMed: 12537880]
[25]. Henderson WG, Eisen S, Goldberg J, True WR, Barnes JE, Vitek ME. The Vietnam Era Twin
Registry: a resource for medical research. Public Health Rep. 1990; 105:368–373. [PubMed:
2116638]
[26]. Dai J, Miller AH, Bremner JD, Goldberg J, Jones L, Shallenberger L, Buckham R, Murrah NV,
Veledar E, Wilson PW, Vaccarino V. Adherence to the mediterranean diet is inversely associated
with circulating interleukin-6 among middle-aged men: a twin study. Circulation. 2008;
117:169–175. [PubMed: 18086924]
[27]. Vaccarino V, Lampert R, Bremner JD, Lee FA, Su S, Maisano C, Murrah NV, Jones L, Jawed F,
Afzal N, Ashraf A, Goldberg J. Depressive symptoms and heart rate variability: evidence for a
shared genetic substrate in a study of twins. Psychosom Med. 2008 in press.
Gehi et al. Page 8













[28]. Zhao J, Cheema FA, Reddy U, Bremner JD, Su S, Goldberg J, Snieder H, Vaccarino V.
Heritability of flow-mediated dilation: a twin study. J Thromb Haemost. 2007; 5:2386–2392.
[PubMed: 17848176]
[29]. Scherrer JF, Xian H, Bucholz KK, Eisen SA, Lyons MJ, Goldberg J, Tsuang M, True WR. A
twin study of depression symptoms, hypertension, and heart disease in middle-aged men.
Psychosom Med. 2003; 65:548–557. [PubMed: 12883104]
[30]. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss
RM, Savage PJ, Smith SC Jr. Spertus JA, Costa F. Diagnosis and management of the metabolic
syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation. 2005; 112:2735–2752. [PubMed: 16157765]
[31]. Heart rate variability. standards of measurement, physiological interpretation and clinical use.
Task Force of the European Society of Cardiology and the North American Society of Pacing
and Electrophysiology. Circulation. 1996; 93:1043–1065. [PubMed: 8598068]
[32]. Rottman JN, Steinman RC, Albrecht P, Bigger JT Jr. Rolnitzky LM, Fleiss JL. Efficient
estimation of the heart period power spectrum suitable for physiologic or pharmacologic studies.
Am J Cardiol. 1990; 66:1522–1524. [PubMed: 2252008]
[33]. Lampert R, Ickovics JR, Viscoli CJ, Horwitz RI, Lee FA. Effects of propranolol on recovery of
heart rate variability following acute myocardial infarction and relation to outcome in the Beta-
Blocker Heart Attack Trial. Am J Cardiol. 2003; 91:137–142. [PubMed: 12521623]
[34]. Richardson MT, Ainsworth BE, Wu HC, Jacobs DR Jr. Leon AS. Ability of the Atherosclerosis
Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity. Int J
Epidemiol. 1995; 24:685–693. [PubMed: 8550264]
[35]. Beck, A.; Steer, R.; Brown, G. Beck Depression Inventory Manual. 2nd ed.. Psychological
Corporation; San Antonio, TX: 1996.
[36]. Carlin JB, Gurrin LC, Sterne JA, Morley R, Dwyer T. Regression models for twin studies: a
critical review. Int J Epidemiol. 2005; 34:1089–1099. [PubMed: 16087687]
[37]. Aadahl M, Kjaer M, Jorgensen T. Associations between overall physical activity level and
cardiovascular risk factors in an adult population. European journal of epidemiology. 2007;
22:369–378. [PubMed: 17333472]
[38]. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME. The association
among autonomic nervous system function, incident diabetes, and intervention arm in the
Diabetes Prevention Program. Diabetes Care. 2006; 29:914–919. [PubMed: 16567837]
[39]. Chen CC, Li TC, Chang PC, Liu CS, Lin WY, Wu MT, Li CI, Lai MM, Lin CC. Association
among cigarette smoking, metabolic syndrome, and its individual components: the metabolic
syndrome study in Taiwan. Metabolism. 2008; 57:544–548. [PubMed: 18328358]
[40]. Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE. Effects of smoking on 24-h ambulatory
blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus
patients. Am J Hypertens. 1998; 11:1093–1099. [PubMed: 9752895]
[41]. Aso Y, Wakabayashi S, Nakano T, Yamamoto R, Takebayashi K, Inukai T. High serum high-
sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic
overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome.
Metabolism. 2006; 55:1014–1021. [PubMed: 16839835]
[42]. Kuch B, Hense HW, Sinnreich R, Kark JD, von Eckardstein A, Sapoznikov D, Bolte HD.
Determinants of short-period heart rate variability in the general population. Cardiology. 2001;
95:131–138. [PubMed: 11474158]
[43]. Stein PK, Barzilay JI, Domitrovich PP, Chaves PM, Gottdiener JS, Heckbert SR, Kronmal RA.
The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and
the metabolic syndrome: the Cardiovascular Health Study. Diabet Med. 2007; 24:855–863.
[PubMed: 17403115]
[44]. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic
syndrome. Ann N Y Acad Sci. 2006; 1083:129–152. [PubMed: 17148737]
[45]. Buijs RM, Kreier F. The metabolic syndrome: a brain disease? J Neuroendocrinol. 2006; 18:715–
716. [PubMed: 16879171]
Gehi et al. Page 9













[46]. Sandercock GR, Brodie DA. The role of heart rate variability in prognosis for different modes of
death in chronic heart failure. Pacing Clin Electrophysiol. 2006; 29:892–904. [PubMed:
16923007]
[47]. Taylor JA, Carr DL, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency RR-
interval oscillations in humans. Circulation. 1998; 98:547–555. [PubMed: 9714112]
[48]. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is
independently associated with an increased prevalence of metabolic syndrome. Eur Heart J.
2004; 25:735–741. [PubMed: 15120883]
[49]. Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. Altered
cardiovascular variability in obstructive sleep apnea. Circulation. 1998; 98:1071–1077. [PubMed:
9736593]
Gehi et al. Page 10














Percent Change in HRV by number of components compared with no components of the
metabolic syndrome. P values listed are for the trend of increasing number of metabolic
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antidepressant), and creatinine clearance.
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